drugset
drugset / Trial / NCT05995119

Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers

NCT05995119 ↗

Phase 0 Completed 12 enrolled TAHO Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelPrevention

Summary

The goal of this clinical trial is to evaluate the pharmacokinetic profiles and bioequivalence, and to determine the safety and tolerability of the TAH3311 Oral Dissolving Film (ODF) 5mg compared with ELIQUIS® (Apixaban) 5mg Oral Tablet, after single dose under fasted and fed conditions in healthy volunteers.

Timeline

Start
2022-12-05
Primary completion
2022-12-28
Completion
2023-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 5 mg Oral

Indications

No indication recorded.